ASP Isotopes Inc. (ASPI) - Dilution Analysis

10-Q filing | 121.0M shares outstanding

10-Q filing | 91.9M shares outstanding

8-K filing: ASP Isotopes Inc. entered into an underwriting agreement for a registered direct offering of 7,500,000 shares of common stock at $8.00 per share, with the Underwriters purchasing the shares at $7.52 per share, resulting in estimated net proceeds of $56.2 million. ($60.0M proceeds)

8-K filing: ASP Isotopes Inc. entered into an underwriting agreement for a registered direct offering of 7,518,797 shares of common stock at $6.65 per share, with the offering expected to close on or about June 3, 2025. ($46.8M proceeds)

8-K filing: ASP Isotopes Inc. issued 1,294,778 shares of common stock to Armistice Capital Master Fund Ltd. and another warrant holder, receiving approximately $4.9 million in gross proceeds from the exercise of warrants. ($4.9M proceeds)

8-K filing: ASP Isotopes Inc. will issue up to 14,270,000 shares of its common stock to acquire all of the issued ordinary shares of Renergen Limited, with Renergen's securityholders owning approximately 16% of the combined entity post-transaction.

10-Q filing | 69.5M shares outstanding

S-3 filing: Aspen Group, Inc. files an S-3 form to register a shelf offering of common stock, preferred stock, and debt securities, with an aggregate offering price of up to $100 million.

10-K filing | 72.1M shares outstanding

10-Q filing | 71.4M shares outstanding

8-K filing: ASP Isotopes Inc. completed a public offering of 2,754,250 shares of common stock at $6.75 per share, resulting in net proceeds of approximately $17.1 million. ($17.1M proceeds)

8-K filing: ASP Isotopes Inc. closed its underwritten public offering of shares of its common stock, selling 2,754,250 shares at $6.75 per share, resulting in gross proceeds of $18.6 million. ($18.6M proceeds)

10-Q filing | 48.9M shares outstanding

8-K filing: ASP Isotopes Inc. announced the closing of a public offering of shares of its common stock, selling 13,800,000 shares at $2.50 per share, resulting in gross proceeds of $34.5 million. ($34.5M proceeds)

8-K filing: ASP Isotopes Inc. entered into an underwriting agreement with Canaccord Genuity LLC for a public offering of 12,000,000 shares of common stock at $2.50 per share, with the underwriter having an option to purchase an additional 1,800,000 shares. ($30.0M proceeds)

S-3 filing: Aspira Women's Health Inc. filed an S-3 form on 2024-05-31, indicating a shelf offering of common stock, preferred stock, and debt securities, with a total proposed amount of $50,000,000.

10-Q filing | 48.9M shares outstanding

S-3 filing: This S-3 filing covers the resale of up to 1,225,000 shares of common stock issuable upon the exercise of warrants held by the selling stockholder.

10-K filing | 48.9M shares outstanding

8-K filing: ASP Isotopes Inc. entered into a warrant inducement agreement with a holder to exercise existing warrants for 3,164,557 shares at $1.75 per share, resulting in gross proceeds of approximately $5.5 million, and issued new warrants to purchase 1,225,000 shares. ($5.5M proceeds)

S-1 filing: The filing describes a private placement offering where the company issued shares of common stock and warrants. It also mentions the engagement of H.C. Wainwright & Co., LLC as the placement agent and the issuance of warrants to the placement agent.

10-Q filing | 35.9M shares outstanding

8-K filing: ASP Isotopes Inc. entered into a Share Purchase Agreement with Nucleonics Imaging Proprietary Limited to purchase 51% of the issued share capital of Pet Labs Pharmaceuticals Proprietary Limited for $2,000,000, with an option to purchase the remaining 49% for $2,200,000. ($2.0M proceeds)

8-K filing: ASP Isotopes Inc. entered into Securities Purchase Agreements to issue and sell 9,952,510 shares of common stock for approximately $9.1 million in a private placement. ($9.1M proceeds)

10-Q filing | 35.9M shares outstanding

10-Q filing | 35.9M shares outstanding

10-K filing | 35.9M shares outstanding

8-K filing: ASP Isotopes Inc. closed a private placement offering on March 17, 2023, issuing 3,167,557 shares of common stock and warrants to purchase up to 3,167,557 shares, at a purchase price of $1.58 per share and warrant, for gross proceeds of approximately $5 million. ($5.0M proceeds)

10-Q filing | 34.4M shares outstanding

8-K filing: ASP Isotopes Inc. closed a public offering of 1,250,000 shares of common stock at $4.00 per share, resulting in gross proceeds of approximately $5.0 million. ($5.0M proceeds)

S-1/A filing: This S-1/A filing relates to an initial public offering of common stock with an anticipated price between $4.00 and $5.00 per share. The underwriters have an option to purchase additional shares.

S-1/A filing: This S-1/A filing indicates an initial public offering of common stock with an expected price between $4.00 and $5.00 per share. The underwriters have an option to purchase additional shares. The closing of this offering is contingent upon the successful listing of our Common Stock on the Nasdaq Capital Market.

S-1/A filing: This is an S-1/A filing for an initial public offering of common stock with an anticipated price between $4.00 and $5.00 per share. The underwriters have an option to purchase an additional 225,000 shares. Selling stockholders are offering an additional 2,057,500 shares, but the company will not receive proceeds from those sales.

S-1/A filing: This S-1/A filing relates to a proposed initial public offering of common stock with an anticipated price between $5.00 and $7.00 per share, with Revere Securities LLC as the sole book-running manager, including an underwriter option to purchase additional shares.

S-1/A filing: This S-1/A filing indicates an initial public offering of common stock with an expected price between $5.00 and $7.00 per share. The underwriters have an option to purchase up to an additional 300,000 shares.

S-1 filing: S-1 filing for an initial public offering, including an option for underwriters to purchase additional shares and an offering of shares by selling stockholders.